Basel, October 29, 2025 – Novartis today presented new ianalumab data in Sjögren’s disease, the second most prevalent rheumatic autoimmune disease 2, at a late-breaker presentation during the American ...
Sales growth was driven by continued strong execution on priority brands including Kisqali (+68% cc), Kesimpta (+44% cc), Pluvicto (+45% cc) and Scemblix (+95% cc) Core operating income margin 1 was ...
Transaction strengthens neuroscience franchise for Novartis with three late-stage programs that address genetic neuromuscular diseases; ...
PluvictoTM plus standard of care (ARPI + ADT) significantly reduced risk of progression or death by 28% (HR 0.72) versus SoC alone, with positive trend in OS (HR 0.84) in PSMA+ metastatic ...
After 5 years, Kisqali ® plus endocrine therapy consistently shows significant and clinically meaningful benefit in invasive disease-free survival 1 Kisqali remains the only CDK4/6 inhibitor ...
Acquisition of Kate Therapeutics enhances and strengthens Novartis strategic priorities in gene therapy and neuroscience innovation Transaction includes enabling technology platforms and therapeutic ...
. Novartis is providing the information in this press release as of this date, and Novartis does not undertake any obligation to update any forward-looking statements contained in this press release ...
Cell Therapies Pty Ltd has become the first approved CAR-T commercial manufacturing site in Australia, providing potentially faster access to CAR-T therapies to eligible patients in the region with ...
Explore opportunities with Novartis below.
Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.
Our leaders in Indonesia are experienced professionals, both in global and local pharmaceutical industry.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback